Emoksikard

General characteristics. Structure:

Active ingredient: 150 mg of a metiletilpiridinol of a hydrochloride in 1 ampoule.

Excipients: sodium sulfite anhydrous, dinatrium phosphate a dihydrate, water for injections.

Pharmacological properties:

Pharmacodynamics. Metiletilpiridinol exerts beneficial effect on system of a blood coagulation: slows down aggregation of thrombocytes, reduces the general index of coagulation, extends a blood clotting time. Strengthens process of a fibrinolysis. Improves microcirculation. Reduces permeability of a vascular wall.

Metiletilpiridinol stabilizes membranes of cells of blood vessels and erythrocytes, increases resistance of erythrocytes to a mechanical injury and hemolysis. Has angioprotektorny properties.

Effectively inhibits free radical oxidation of lipids of biomembranes, increases activity of antioxidant enzymes. Stabilizes R-450 cytochrome, possesses anti-toxic action. In the extreme situations which are followed by strengthening of peroxide oxidation of lipids and a hypoxia optimizes biopower processes.

Metiletilpiridinol reduces symptoms of cerebral haemo dysfunction. Increases resistance of a brain to a hypoxia and ischemia. At disturbances of cerebral circulation (ischemic and hemorrhagic) promotes correction of vegetative dysfunctions, facilitates recovery of integrative activity of a brain, improves mnestichesky functions.

Has hypolipidemic effect, reduces synthesis of triglycerides.

Drug possesses the expressed cardioprotective action. Expands coronary vessels, reduces ischemic injury of a myocardium. At a myocardial infarction limits necrosis center size, accelerates reparative processes, contributes to normalization of metabolism of a myocardium. Exerts beneficial effect on the clinical course of a myocardial infarction, reducing the frequency of development of an acute heart failure. Promotes regulation of oxidation-reduction system at a circulatory unefficiency.

Pharmacokinetics. At intravenous administration in a dose of 10 mg/ml the low period of semi-elimination is noted (T1/2 — 18 min. that testifies to the high speed of elimination of drug from blood. Elimination constant size — 0,041 min.; the general clearance of Cl — 214,8 ml/min.; the seeming volume of distribution of Vkazh. — 5,2 l.

Drug quickly gets into bodies and fabrics where there is its deposition and metabolism. 5 metabolites of a metiletilpiridinol presented by the dialkylated and conjugated products of its transformation are revealed. Metabolites of a metiletilpiridinol are excreted by kidneys. In significant amounts in a liver 2-ethyl-6-methyl-3-oxypyridine-phosphate is found.

Indications to use:

In neurology and neurosurgery in complex therapy:

· hemorrhagic stroke,

· an ischemic stroke in the pool of an internal carotid artery and in vertebrobazilyarny system,

· passing disturbances of cerebral circulation,

· chronic insufficiency of cerebral circulation,

· the craniocereberal injury which is followed by brain bruises;

· the postoperative period at the patients with a craniocereberal injury operated concerning Epi - the subdural and intracerebral hematomas which are combined with brain bruises

· before - and the postoperative period at patients with arterial aneurisms and arteriovenous malformation of vessels of a brain.

In cardiology in complex therapy:

· acute myocardial infarction,

· prevention of "reperfusion syndrome",

· unstable stenocardia.

Route of administration and doses:

Doses, duration of a course of treatment are defined individually.

In neurology and neurosurgery apply intravenously kapelno in a daily dose 5-10 mg/kg within 10-12 days. Before introduction Emoksikard part in 200 ml of solution of sodium of chloride isotonic. Enter with a speed of 20-30 thaws a minute. In the subsequent 2 — 3 times a day within 10 — 30 days pass to intramuscular introduction 2-10 ml 30 mg/ml of solution (60 — 300 mg).

In cardiology begin with intravenous drop (20-40 drops a minute) introductions of 20 — 30 ml 30 mg/ml of solution of a metiletilpiridinol (600-900 mg) to 200 ml of solution of sodium of chloride of isotonic 1 — 3 time a day within 5 — 15 days depending on the course of a disease, with the subsequent transition to intramuscular introduction of 2 — 10 ml 30 mg/ml of solution of a metiletilpiridinol (60 — 300 mg) 2 — 3 times a day within 10 — 30 days.

Treatment methylethylpyrrolidinoscrap, in case of its intravenous and intramuscular administration, should be carried out under control of arterial pressure and a functional condition of coagulant and anticoagulative systems of blood.

Features of use:

It is necessary to control constantly during treatment the arterial pressure and coagulability of blood.

Medicine does not influence ability to manage vehicles and the machine equipment.

Side effects:

As a rule, adverse effects at use of drug are not observed.

At intravenous administration — a burning sensation on the vein course; increase in arterial pressure, excitement or drowsiness can be noted. At predisposition to allergic reactions emergence of an itch and erubescence is in rare instances observed.

Interaction with other medicines:

α-tocopherol acetate exponentiates antioxidant effect of a metiletilpiridinol.

Metiletilpiridinol is not recommended to mix with other injection means in one syringe.

Contraindications:

Individual intolerance, pregnancy, the lactation period, children's age up to 18 years.

Overdose:

At overdose strengthening of expressiveness of side effects of drug is possible.

Symptoms: increase in arterial pressure, excitement or drowsiness, a headache, pain in heart, nausea, discomfort in epigastric area. Disturbance of coagulability of blood is possible.

Treatment: drug withdrawal, performing symptomatic therapy, a specific antidote is not present.

Storage conditions:

In the place protected from light, at a temperature not over 30 ºС. To store in the place, unavailable to children. A period of validity - 2 years. Medicine cannot be used after the term specified on the label.

Issue conditions:

According to the recipe

Packaging:

In ampoules on 5 ml. On 10 ampoules together with a leaf insert place in a box from a cardboard; on 5 ampoules in the blister from a PVC film, on 2 blisters together with a leaf insert place in a pack from a cardboard; on 5 or 10 ampoules together with a leaf insert in a pack from a cardboard.